Prophylaktische intraoperative adjuvante Therapie mit 5-Fluorouracil und Heparin zur Prävention der proliferativen Vitreoretinopathie (PVR) in Hochrisikopatienten mit primärer rhegmatogener Netzhautablösung

• Antragstellerin: Privatdozentin Dr. Friederike Schaub, seit 8/2019
• Fachliche Zuordnung: Augenheilkunde
• Förderung: Förderung von 2015 bis 2021
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 264589742

Proliferative vitreoretinopathy (PVR) is the major cause for postoperative failure after surgery for rhegmatogenous retinal detachment (RRD). Fibrovascular scars lead to secondary retinal detachments, which often require multiple extensive operations to achieve re-attachment. Despite advances in the surgical management of PVR, the visual prognosis is poor and many patients become legally blind. Although several studies using chemotherapeutic agents have been undertaken, so far there is no standard therapy to prevent PVR. Two independent trials used an intravitreal infusion with 5-Fluorouracil (5-FU) plus low molecular weight heparin (LMWH) during surgery once in high-risk patients and once in unselected patients. In high-risk patients 5-FU + LMWH reduced PVR rates by 50%, while in unselected patients it did not. A review of the COCHRANE-collaboration led to the recommendation to conduct a clinical randomized trial using 5-FU + LMWH in high-risk patients. We have established non-invasive laser flare photometry as a novel tool for fast and precise estimation of the risk for PVR re-detachments. By selecting high-risk patients with this method we plan to use intraoperative intravitreal 5-FU + LMWH as a prophylactic therapy in a placebo controlled, randomized, double blind trial. We aim to reduce the incidence of PVR in the treatment group. 5-FU + LMWH would be the first effective prophylactic standard treatment to prevent PVR and decrease the incidence of blindness in patients with retinal detachments. Laser flare photometry would limit the treatment to those at high risk.

• DFG-Verfahren: Klinische Studien
• Beteiligte Person: Dr. Robert Hörster
• Ehemalige Antragsteller: Professor Dr. Sascha Fauser, bis 3/2016; Professor Dr. Bernd Kirchhof, von 4/2016 bis 7/2019